{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:54:40Z","timestamp":1761494080755,"version":"build-2065373602"},"reference-count":117,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100020758","name":"Fujian Association for Science and Technology","doi-asserted-by":"publisher","award":["202028"],"award-info":[{"award-number":["202028"]}],"id":[{"id":"10.13039\/100020758","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81902484"],"award-info":[{"award-number":["81902484"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2020M670864"],"award-info":[{"award-number":["2020M670864"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hepatobiliary & Pancreatic Diseases International"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.hbpd.2023.08.003","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T11:50:16Z","timestamp":1691063416000},"page":"4-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recent advances in promising drugs for primary prevention of gastroesophageal variceal bleeding with cirrhotic portal hypertension"],"prefix":"10.1016","volume":"23","author":[{"given":"Ji-Yao","family":"Sheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Fan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Sheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hbpd.2023.08.003_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-017-9827-9","article-title":"The portal hypertension syndrome: etiology, classification, relevance, and animal models","volume":"12","author":"Bosch","year":"2018","journal-title":"Hepatol Int"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0002","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.mayocp.2018.12.020","article-title":"Portal hypertension and related complications: diagnosis and management","volume":"94","author":"Simonetto","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0003","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.hbpd.2022.09.004","article-title":"Impact of cirrhosis-related complications on posttransplant survival in patients with acute-on-chronic liver failure","volume":"22","author":"Zhu","year":"2023","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0004","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/apt.15320","article-title":"Uptake of endoscopic screening for gastroesophageal varices and factors associated with variceal bleeding in patients with chronic hepatitis C infection and compensated cirrhosis, 2005-2016: a national database linkage study","volume":"50","author":"McDonald","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3350\/cmh.2017.0064","article-title":"Prevention and management of gastroesophageal varices","volume":"24","author":"Seo","year":"2018","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0006","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12072-008-9096-8","article-title":"Primary prophylaxis of gastroesophageal variceal bleeding: consensus recommendations of the Asian Pacific Association for the Study of the Liver","volume":"2","author":"Sarin","year":"2008","journal-title":"Hepatol Int"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0007","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases","volume":"65","author":"Garcia-Tsao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0008","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0009","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.3748\/wjg.v26.i40.6111","article-title":"Cirrhotic portal hypertension: from pathophysiology to novel therapeutics","volume":"26","author":"Gunarathne","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0010","first-page":"330","article-title":"The molecular basis of portal hypertension","volume":"128","author":"Rockey","year":"2017","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0011","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.hbpd.2021.04.010","article-title":"Mitochondria: a critical hub for hepatic stellate cells activation during chronic liver diseases","volume":"20","author":"Ezhilarasan","year":"2021","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0012","article-title":"Portal hypertension in cirrhosis: pathophysiological mechanisms and therapy","volume":"3","author":"Iwakiri","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0013","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/j.jhep.2015.01.003","article-title":"Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments","volume":"62","author":"Bosch","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0014","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1136\/gut.2007.144584","article-title":"Mechanisms of extrahepatic vasodilation in portal hypertension","volume":"57","author":"Hennenberg","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jcma.2014.10.004","article-title":"Molecular mechanisms of circulatory dysfunction in cirrhotic portal hypertension","volume":"78","author":"Ho","year":"2015","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0016","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2016.11.001","article-title":"Beta adrenergic blockade and decompensated cirrhosis","volume":"66","author":"Reiberger","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0017","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/hep.24148","article-title":"Nuclear receptors in liver disease","volume":"53","author":"Wagner","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0018","article-title":"Beta-blockers in cirrhosis: evidence-based indications and limitations","volume":"2","author":"Rodrigues","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0019","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.23775","article-title":"Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites","volume":"52","author":"Serst\u00e9","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0020","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1053\/j.gastro.2014.03.005","article-title":"Nonselective \u03b2 blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"146","author":"Mandorfer","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0021","doi-asserted-by":"crossref","first-page":"532","DOI":"10.4253\/wjge.v7.i5.532","article-title":"Is it time to replace propranolol with carvedilol for portal hypertension?","volume":"7","author":"Abid","year":"2015","journal-title":"World J Gastrointest Endosc"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010902","article-title":"Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis","volume":"6","author":"Li","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0023","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.dld.2016.09.013","article-title":"Beta blockers and cirrhosis, 2016","volume":"49","author":"Mandorfer","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0024","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.4254\/wjh.v8.i24.1012","article-title":"Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension","volume":"8","author":"Ferrarese","year":"2016","journal-title":"World J Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0025","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/17425255.2020.1801634","article-title":"An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins","volume":"16","author":"Hirota","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0026","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jhep.2012.08.026","article-title":"The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins","volume":"58","author":"Marrone","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0027","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2002-01-0046","article-title":"Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Kr\u00fcppel-like factor (KLF2)","volume":"100","author":"Dekker","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0028","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/gut.2010.220913","article-title":"Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver","volume":"60","author":"Gracia-Sancho","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0029","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11894-017-0584-7","article-title":"Use of statins in patients with chronic liver disease and cirrhosis: current views and prospects","volume":"19","author":"Vargas","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0030","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1535370219898141","article-title":"Mechanisms of liver fibrosis and its role in liver cancer","volume":"245","author":"Dhar","year":"2020","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0031","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jhep.2010.04.025","article-title":"Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells","volume":"53","author":"Trebicka","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0032","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1053\/j.gastro.2018.07.022","article-title":"Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension","volume":"155","author":"Tripathi","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0033","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2007.01.020","article-title":"Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats","volume":"46","author":"Abraldes","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0034","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1136\/gutjnl-2014-308338","article-title":"KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins","volume":"64","author":"Marrone","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0035","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","article-title":"Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis","volume":"126","author":"Zafra","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0036","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12876-019-1147-1","article-title":"Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis","volume":"19","author":"Gu","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0037","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/MEG.0000000000001006","article-title":"Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study","volume":"30","author":"Bishnu","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0038","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","article-title":"Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Pose","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0039","doi-asserted-by":"crossref","first-page":"10389","DOI":"10.1111\/jcmm.16968","article-title":"Celecoxib reduces hepatic vascular resistance in portal hypertension by amelioration of endothelial oxidative stress","volume":"25","author":"Tai","year":"2021","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0040","doi-asserted-by":"crossref","first-page":"e69309","DOI":"10.1371\/journal.pone.0069309","article-title":"Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis","volume":"8","author":"Gao","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0041","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00210-016-1263-1","article-title":"Antifibrotic effect of meloxicam in rat liver: role of nuclear factor kappa B, proinflammatory cytokines, and oxidative stress","volume":"389","author":"Hassan","year":"2016","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0042","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.3390\/ijms21176223","article-title":"Phosphodiesterases in the liver as potential therapeutic targets of cirrhotic portal hypertension","volume":"21","author":"Kreisel","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0043","doi-asserted-by":"crossref","first-page":"10372","DOI":"10.3390\/ijms221910372","article-title":"Cyclic GMP in liver cirrhosis-role in pathophysiology of portal hypertension and therapeutic implications","volume":"22","author":"Kreisel","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0044","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.3748\/wjg.v24.i38.4356","article-title":"Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension","volume":"24","author":"Schaffner","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0045","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1478-3231.2004.00892.x","article-title":"Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients","volume":"24","author":"Colle","year":"2004","journal-title":"Liver Int"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0046","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1471-230X-9-69","article-title":"Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver","volume":"9","author":"Halverscheid","year":"2009","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0047","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.dld.2014.10.018","article-title":"The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study","volume":"47","author":"Kreisel","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0048","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3748\/wjg.v24.i3.438","article-title":"Beneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: a case report with 8 years follow-up","volume":"24","author":"Deibert","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0049","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1177\/2050640620944140","article-title":"Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats","volume":"8","author":"Brusilovskaya","year":"2020","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0050","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.3390\/cells8111356","article-title":"Natural sulfur-containing compounds: an alternative therapeutic strategy against liver fibrosis","volume":"8","author":"Milito","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0051","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.niox.2019.10.008","article-title":"Modulation of endothelium-derived nitric oxide production and activity by taurine and taurine-conjugated bile acids","volume":"94","author":"Guizoni","year":"2020","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0052","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.3748\/wjg.15.4529","article-title":"Attenuation of portal hypertension by natural taurine in rats with liver cirrhosis","volume":"15","author":"Liang","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0053","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/apt.14377","article-title":"Randomised clinical study: the effects of oral taurine 6g\/day vs placebo on portal hypertension","volume":"47","author":"Schwarzer","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0054","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.cmet.2009.03.012","article-title":"AMPK: an emerging drug target for diabetes and the metabolic syndrome","volume":"9","author":"Zhang","year":"2009","journal-title":"Cell Metab"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0055","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00109-019-01746-4","article-title":"AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model","volume":"97","author":"Hu","year":"2019","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0056","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6181432","article-title":"AICAR-induced AMPK activation inhibits the noncanonical NF-\u03baB pathway to attenuate liver injury and fibrosis in BDL rats","volume":"2018","author":"Zhu","year":"2018","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0057","first-page":"124","article-title":"Soluble epoxide hydrolase inhibition in liver diseases: a review of current research and knowledge gaps","volume":"9","author":"Warner","year":"2020","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0058","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.prostaglandins.2017.08.004","article-title":"Inhibition of soluble epoxide hydrolase lowers portal hypertension in cirrhotic rats by ameliorating endothelial dysfunction and liver fibrosis","volume":"131","author":"Deng","year":"2017","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0059","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/bcp.12855","article-title":"Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor","volume":"81","author":"Lazaar","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0060","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jhep.2019.06.017","article-title":"FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis","volume":"71","author":"Sorribas","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0061","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","article-title":"The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction","volume":"66","author":"Schwabl","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0062","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats","volume":"59","author":"Verbeke","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0063","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.5604\/01.3001.0010.5500","article-title":"Bile acids and portal hypertension","volume":"16","author":"Pablo Arab","year":"2017","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0064","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/hep.26627","article-title":"Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo","volume":"59","author":"Fallowfield","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0065","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.biochi.2021.06.001","article-title":"Relaxin in hepatic fibrosis: what is known and where to head?","volume":"187","author":"Ezhilarasan","year":"2021","journal-title":"Biochimie"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0066","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s13063-020-4203-9","article-title":"A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP)","volume":"21","author":"Gifford","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0067","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/hep.26520","article-title":"Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats","volume":"58","author":"Rosado","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0068","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jhep.2012.12.012","article-title":"Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats","volume":"58","author":"Di Pascoli","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0069","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/liv.13436","article-title":"Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats","volume":"37","author":"Vilaseca","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0070","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jhep.2012.09.010","article-title":"Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats","volume":"58","author":"Guillaume","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175115","article-title":"Diammonium glycyrrhizinate ameliorates portal hypertension by regulating portal macrophage oxidation and superoxide dismutase 3","volume":"929","author":"Zhao","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0072","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.3748\/wjg.v23.i25.4529","article-title":"Glutamine prevents oxidative stress in a model of portal hypertension","volume":"23","author":"Zabot","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0073","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.21228","article-title":"The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis","volume":"44","author":"Matei","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0074","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2008.04.014","article-title":"Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats","volume":"49","author":"Matei","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0075","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3346\/jkms.2014.29.3.392","article-title":"Relationship between tetrahydrobiopterin and portal hypertension in patients with chronic liver disease","volume":"29","author":"Hong","year":"2014","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0076","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.hbpd.2020.07.004","article-title":"Combined hepatocellular-cholangiocarcinoma: an update on epidemiology, classification, diagnosis and management","volume":"19","author":"Schizas","year":"2020","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0077","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0076-6879(05)07047-3","article-title":"Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","volume":"407","author":"Adnane","year":"2006","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0078","first-page":"2498","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Palmer","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0079","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.hbpd.2020.12.016","article-title":"Transjugular intrahepatic portosystemic shunt is effective in patients with chronic portal vein thrombosis and variceal bleeding","volume":"20","author":"Sun","year":"2021","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0080","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.hbpd.2021.12.004","article-title":"Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: a narrative review","volume":"21","author":"Tao","year":"2022","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0081","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/hep.22758","article-title":"Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats","volume":"49","author":"Mejias","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0082","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/hepr.13531","article-title":"Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: a prospective cohort study","volume":"50","author":"Hidaka","year":"2020","journal-title":"Hepatol Res"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0083","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1476-5381.2009.00158.x","article-title":"Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis","volume":"157","author":"Hennenberg","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0084","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1478-3231.2005.01142.x","article-title":"Fasudil hydrochloride hydrate, a Rho-kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells","volume":"25","author":"Fukushima","year":"2005","journal-title":"Liver Int"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0085","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2036.2011.04896.x","article-title":"The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma\u2013a pilot study","volume":"35","author":"Pinter","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0086","doi-asserted-by":"crossref","first-page":"G1191","DOI":"10.1152\/ajpgi.00252.2011","article-title":"Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats","volume":"302","author":"D'Amico","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0087","article-title":"Thalidomide improves the intestinal mucosal injury and suppresses mesenteric angiogenesis and vasodilatation by down-regulating inflammasomes-related cascades in cirrhotic rats","volume":"11","author":"Li","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0088","first-page":"1616","article-title":"Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats","volume":"23","author":"Lopez-Talavera","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0089","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.3748\/wjg.v21.i14.4126","article-title":"Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure","volume":"21","author":"Theodorakis","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0090","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/diacare.23.11.1605","article-title":"Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group","volume":"23","author":"Aronoff","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0091","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jhep.2014.01.025","article-title":"Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats","volume":"60","author":"Schwabl","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0092","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jcma.2017.08.010","article-title":"The effects of pioglitazone in cirrhotic rats with hepatopulmonary syndrome","volume":"80","author":"Cheng","year":"2017","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0093","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.lfs.2013.08.018","article-title":"Functional relevance of the cannabinoid receptor 2 - heme oxygenase pathway: a novel target for the attenuation of portal hypertension","volume":"93","author":"Steib","year":"2013","journal-title":"Life Sci"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0094","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/hep.25625","article-title":"Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats","volume":"56","author":"Huang","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0095","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mvr.2016.12.009","article-title":"Effects of nuclear factor-E2-related factor 2\/heme oxygenase 1 on splanchnic hemodynamics in experimental cirrhosis with portal hypertension","volume":"111","author":"Qin","year":"2017","journal-title":"Microvasc Res"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0096","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1177\/1535370220949148","article-title":"Endothelin-1 in portal hypertension: the intricate role of hepatic stellate cells","volume":"245","author":"Ezhilarasan","year":"2020","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0097","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1517\/13543780802680186","article-title":"Endothelin receptor antagonism in portal hypertension","volume":"18","author":"Pitts","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0098","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/liv.14757","article-title":"Effect of ET-A blockade on portal pressure and hepatic arterial perfusion in patients with cirrhosis: a proof of concept study","volume":"41","author":"Zipprich","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0099","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.048884","article-title":"Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH","volume":"14","author":"Bravo","year":"2021","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0100","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/eci.12636","article-title":"Endothelin receptor blockers reduce shunting and angiogenesis in cirrhotic rats","volume":"46","author":"Hsu","year":"2016","journal-title":"Eur J Clin Invest"},{"issue":"Suppl 1","key":"10.1016\/j.hbpd.2023.08.003_bib0101","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.jhep.2020.11.013","article-title":"The microbiota in cirrhosis and its role in hepatic decompensation","volume":"75","author":"Trebicka","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0102","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jhep.2013.07.044","article-title":"Pathological bacterial translocation in liver cirrhosis","volume":"60","author":"Wiest","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0103","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1478-3231.2008.01850.x","article-title":"Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial","volume":"29","author":"Kemp","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0104","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/hep.31708","article-title":"The use of rifaximin in patients with cirrhosis","volume":"74","author":"Caraceni","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0105","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1159\/000375352","article-title":"Infection as a trigger for portal hypertension","volume":"33","author":"Steib","year":"2015","journal-title":"Dig Dis"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0106","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1159\/000360514","article-title":"Coagulopathy in liver diseases: complication or therapy?","volume":"32","author":"Bianchini","year":"2014","journal-title":"Dig Dis"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0107","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2015.12.003","article-title":"Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats","volume":"64","author":"Cerini","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0108","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.clinre.2013.02.007","article-title":"Prophylactic enoxaparin in decompensated cirrhosis: a prevention of portal hypertension-related complications?","volume":"37","author":"Rudler","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0109","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/liv.13510","article-title":"Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis","volume":"38","author":"Fortea","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0110","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/hep.29084","article-title":"The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells","volume":"65","author":"Vilaseca","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0111","doi-asserted-by":"crossref","first-page":"e2409","DOI":"10.6061\/clinics\/2021\/e2409","article-title":"Efficacy and safety of emricasan in liver cirrhosis and\/or fibrosis","volume":"76","author":"Mu","year":"2021","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0112","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jhep.2019.12.010","article-title":"Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension","volume":"72","author":"Garcia-Tsao","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0113","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/hep.30199","article-title":"Emricasan (IDN-6556) lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension","volume":"69","author":"Garcia-Tsao","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0114","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.2147\/DDDT.S315724","article-title":"Non-alcoholic steatohepatitis (NASH) - a review of a crowded clinical landscape, driven by a complex disease","volume":"15","author":"Fraile","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0115","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0116","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/hep.23596","article-title":"Treatment with the leukotriene inhibitor montelukast for 10 days attenuates portal hypertension in rat liver cirrhosis","volume":"51","author":"Steib","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2023.08.003_bib0117","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/gast.2002.31040","article-title":"5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes","volume":"122","author":"Graupera","year":"2002","journal-title":"Gastroenterology"}],"container-title":["Hepatobiliary & Pancreatic Diseases International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499387223001224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499387223001224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:44:24Z","timestamp":1761493464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499387223001224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":117,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1499387223001224"],"URL":"https:\/\/doi.org\/10.1016\/j.hbpd.2023.08.003","relation":{},"ISSN":["1499-3872"],"issn-type":[{"type":"print","value":"1499-3872"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in promising drugs for primary prevention of gastroesophageal variceal bleeding with cirrhotic portal hypertension","name":"articletitle","label":"Article Title"},{"value":"Hepatobiliary & Pancreatic Diseases International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hbpd.2023.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}